目的 探讨益肺胶囊联合茚达特罗治疗慢性阻塞性肺疾病稳定期的临床效果。方法 选取2018年1月—2018年11月淮南新华医疗集团新华医院收治的68例慢性阻塞性肺疾病稳定期患者，随机分为对照组和治疗组，每组各34例。对照组吸入马来酸茚达特罗吸入粉雾剂，150 μg/次，1次/d。治疗组在对照组基础上口服益肺胶囊，4粒/次，3次/d。两组均连续治疗14 d。观察两组的临床疗效，比较两组治疗前后肺功能指标、气道黏液高分泌相关症状评分、6 min步行距离（6MWD）、慢性阻塞性肺疾病患者自我评估测试（CAT）问卷评分、外周血嗜酸粒细胞数（EOS#）及血清相关指标的变化情况。结果 治疗后，对照组和治疗组的总有效率分别是76.5%、94.1%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组第1秒用力呼气容积（FEV1）与用力肺活量（FVC）比值（FEV1/FVC）、最大呼气流量（PEF）、FEV1占预计值百分比（FEV1% pred）均较治疗前显著上升，同组治疗前后比较差异有统计学意义（P<0.05）；治疗后，治疗组这些肺功能指标显著高于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组6 min步行距离（6MWD）显著升高，而咳嗽评分、咳痰评分、CAT问卷评分均较治疗前显著降低，同组治疗前后比较差异有统计学意义（P<0.05）；治疗后，治疗组6MWD高于对照组，而咳嗽评分、咳痰评分、CAT问卷评分显著低于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组外周血嗜酸粒细胞数（EOS#）值及血清白三烯B4（LTB4），白介素（IL）-8、8异前列腺素2α（8-iso-PGF_2α）水平较治疗前均显著下降，同组治疗前后比较差异有统计学意义（P<0.05）；治疗后，治疗组EOS#值、LTB4、IL-8、8-iso-PGF_2α水平显著低于对照组，两组比较差异具有统计学意义（P<0.05）。结论 益肺胶囊联合茚达特罗治疗慢性阻塞性肺疾病稳定期具有较好的临床疗效，能有效减轻患者气道黏液高分泌，保护肺功能，提高活动耐力，缓解炎症反应，抑制氧化应激，改善生活质量，具有一定的临床推广应用价值。

Objective To investigate the clinical effect of Yifei Capsules combined with Yindateluo in treatment of chronic obstructive pulmonary disease. Methods 68 Patients with stable phase of chronic obstructive pulmonary disease in Xinhua Medical Group Xinhua Hospital from January 2018 to November 2018 were randomly divided into control group (34 cases) and treatment group (34 cases). Patients in the control group were given Indacaterol Maleate Powder for Inhalation, 150 μg/time, once daily. Patients in the treatment group were po administered with Yifei Capsules, 4 grains/time, three times daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacy was evaluated, and the changes of pulmonary function indexes, airway mucus hypersecretion related symptom score, 6-min walking distance (6MWD), CAT questionnaire score, eosinophilic granulocyte number in peripheral blood (EOS#), and serum related indexes in two groups were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 76.5% and 94.1%, respectively, and there were differences between two groups (P <0.05). After treatment, FEV1/FVC, PEF, and FEV1%pred in two groups were significantly increased, and there were differences in the same group (P<0.05). After treatment, those pulmonary function indexes in the treatment group were significantly higher than those in the control group, and there were differences between two groups (P<0.05). After treatment, 6MWD in two groups were significantly increased, but cough score, sputum score, and CAT questionnaire score were significantly decreased, and there were differences in the same group (P<0.05). After treatment, 6MWD in the treatment group were higher than those in the control group, but cough score, sputum score, and CAT questionnaire score were lower than those in the control group, and there were differences between two groups (P<0.05). After treatment, EOS, LTB4, IL-8, and 8-iso-PGF_2α in two groups were significantly decreased, and there were differences in the same group (P<0.05). After treatment, EOS, LTB4, IL-8, and 8-iso-PGF_2α in the treatment group were significantly lower than those in the control group, and there were differences between two groups (P<0.05). Conclusion Yifei Capsules combined with Yindateluo has significant effect in treatment of chronic obstructive pulmonary disease, and can effectively reduce the high secretion of airway mucus, and protect lung function, improve activity endurance, and relieve inflammation, inhibit oxidative stress, and improve the life quality, which has a certain clinical application value.